China reported more than 1.2 million cases of adverse drug reactions (ADRs) in 2012, with anti-infection drugs accounting for 40 percent of the total, according to a report from the State Food and Drug Administration (SFDA) Thursday. Highlighting cephalosporin as causing the greatest number of ADR cases among anti-infection drugs, senior SFDA official Yan Min called for manufacturing companies to research the drug's ADR sources more thoroughly. Yan added that the use of anti-infection drugs has been effectively regulated, as the proportion of ADR resulting from these drugs has been continuously dropping. The ADR monitoring report noted that of the 1.2 million ADR cases, 81.6 percent involved chemical-based medicine, while traditional Chinese medicine (TCM) contributed 17.1 percent. Biological products accounted for the rest. New or severe adverse reactions accounted for 20 percent of the total, the report said. As injections took up the lion's share of the total cases with 56.7 percent, Yan urged health institutions to strengthen supervision over their use. Her urge echoed a recent call from the Ministry of Health to implement safer practices after local authorities in northeast China's Liaoning Province confirmed last month that 99 people had contracted hepatitis C at a private clinic from contaminated injections.
GMT 18:35 2018 Thursday ,11 January
Syrian refugee sets himself ablaze at UN office in LebanonGMT 18:48 2018 Tuesday ,09 January
Novo Nordisk woos Belgian nano-drug makerGMT 17:54 2017 Wednesday ,27 December
Medical evacuations begin from besieged Syria rebel bastionGMT 12:14 2017 Monday ,25 December
MoHAP successfully conducts cochlear implant operationGMT 18:24 2017 Sunday ,24 December
Palestinian conjoined twins arrive in RiyadhGMT 19:05 2017 Monday ,18 December
new! magazine names fitness & food editorGMT 17:03 2017 Wednesday ,29 November
Spain reports case of 'mad cow disease'GMT 14:05 2017 Saturday ,11 November
EU can't agree on new licence for controversial glyphosate weedkiller
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor